Request a sponsored account
If your institution has a site license, you may be eligible for a sponsored account.
Enter your organization-affiliated email address below to request or renew your sponsored account.
Enter your organization-affiliated email address below to request or renew your sponsored account.
Latest Stories
The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.
Guest Editorial
Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.
Capitol Hill
Robert F. Kennedy Jr., President-elect Donald Trump’s choice for HHS secretary, is unfit for that role and should not be confirmed, 77 Nobel laureates said in a letter to members of the U.S. Senate.
The NCI Board of Scientific Advisors approved four new concepts and five reissue concepts at a joint meeting of the BSA and the National Cancer Advisory Board Dec. 2-3.
Free
What does the most-read story of 2024 say about the priorities of our readers?
Free
In 2021, The Cancer Letter launched the Cancer History Project, a first-of-its-kind collaborative archive of oncology’s history.
In Brief
Virginia Commonwealth University has been awarded a five-year, $9 million grant from NCI to establish a pioneering Cancer Control Equity Research Center. This initiative aims to enhance the dissemination and implementation of health promotion and cancer prevention services for individuals and families residing in Virginia’s Housing and Urban Development-administered income-based housing communities in the Greater Richmond region and Hampton Roads.
In Brief
Stephen BaylinAndrew FeinbergJohns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center researchers Stephen Baylin and Andrew Feinberg were awarded the 2022–2023 Harvey Prize in the field of Science and Technology by the Technion—Israel Institute of Technology.
In Brief
Lauren Averett Byers, professor of thoracic/head & neck medical oncology at the University of Texas MD Anderson Cancer Center, received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology. The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer, which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.
In Brief
Christopher Seet received a $2.9 million R37 MERIT Award from NCI to advance the development of innovative T cell therapies for cancer. He is an assistant professor of hematology-oncology at the David Geffen School of Medicine at UCLA.
In Brief
Julie In received a $1.9 million grant from the National Institute of Environmental Health Sciences to study the impact of uranium on the cells that line the intestines.
In Brief
Nan ZhangNoam AuslanderNan Zhang and Noam Auslander, the Wistar Institute assistant professors, have both received independent funding totaling $1.2 million over the next three years for cancer research projects from the V Foundation for Cancer Research. The grants are awarded to cancer researchers deemed “V Scholars” and allow Zhang and Auslander to pursue separate projects aimed at new strategies to improve the effectiveness of certain cancer therapies.
Clinical Roundup
The U.S. Preventive Services Task Force posted a draft recommendation statement on screening for cervical cancer.
Clinical Roundup
AstraZeneca and Merckannounced long-term results from the OlympiA phase III trial which showed Lynparza (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival for people with germline BRCA-mutated HER2-negative high-risk early breast cancer.
Clinical Roundup
Eli Lilly and Co. announced results from the phase III EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, in patients with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.
Clinical Roundup
Eli Lilly and Co. announced results from the phase III BRUIN CLL-321 trial evaluating pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase inhibitor in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma previously treated with a covalent BTK inhibitor.
Clinical Roundup
COTA Inc., PreciseDx, and Baptist Health South Florida announced study results validating that the artificial intelligence-enabled PreciseBreast test is equivalent to the Oncotype DX test at predicting breast cancer recurrence. The research was presented at the San Antonio Breast Cancer Symposium.
Clinical Roundup
Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.
Clinical Roundup
For over 50 years, scientists have been on a quest to identify which malignant mutations within the tumor allow rogue cells to break away from the primary tumor and travel through the bloodstream and lymphatic system to metastasize throughout the body. Now, new research suggests an alternative mechanism has been overlooked—elusive mutations driving metastasis may not be developing within the twisted DNA of tumors themselves, but within the patient’s regular, inherited DNA.
Clinical Roundup
Novartis announced results from an updated analysis of the pivotal phase III NATALEE trial of Kisqali (ribociclib) that underscore the extended efficacy beyond the duration of treatment in combination with endocrine therapy. Results showed a sustained reduction in distant recurrence of 28.5% (HR=0.715; 95% CI 0.604-0.847; nominal P<0.0001), compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.
Clinical Roundup
Johnson & Johnson announced data highlighting that Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients with newly diagnosed multiple myeloma, regardless of transplant status.
Clinical Roundup
Nektar Therapeutics announced results of its phase II proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma at the 66th ASH Annual Meeting and Exposition in San Diego.
Clinical Roundup
Kite announced findings from three new analyses for Yescarta (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory large B-cell lymphoma, which were presented at 66th American Society of Hematology annual meeting.
Clinical Roundup
Positive results from the AMPLIFY phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.
Clinical Roundup
Johnson & Johnson announced new frontline data featuring Tecvayli (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance settings.
Clinical Roundup
GSK plc announced statistically significant and clinically meaningful overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus dexamethasone as a second line or later treatment for relapsed or refractory multiple myeloma.
Clinical Roundup
Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.
Clinical Roundup
Johnson & Johnson announced new results from the phase III CARTITUDE-4 study that show a single infusion of Carvykti (ciltacabtagene autoleucel; cilta-cel) significantly increased minimal residual disease negativity rates (10-5) in patients with relapsed or refractory multiple myeloma who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor, compared to standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
Clinical Roundup
Smokers with myelodysplastic syndromes or a precursor condition had elevated levels of genetic mutations linked to the disease, a new study shows. The study also found that heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.
Clinical Roundup
Timothy S. Fenske, Medical College of Wisconsin, presented findings from the ECOG-ACRIN phase III study EA4151, investigating rituximab with or without stem cell transplant in patients With minimal residual disease-negative mantle cell lymphoma in first complete remission, at the 66th ASH Annual Meeting and Exposition in San Diego.
Clinical Roundup
IMUNON Inc. announced additional clinical data from ongoing analyses of results from the company’s phase II OVATION 2 Study of IMNN-001, its investigational interleukin-12 immunotherapy for the treatment of advanced ovarian cancer based on its proprietary TheraPlas technology.
Clinical Roundup
A study in women with breast cancer suggests that low oral doses of minoxidil, taken during or after cancer treatment, appear to regrow hair in most patients and without causing any serious heart-related side effects that require additional therapies or hospitalization.
Clinical Roundup
Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
Clinical Roundup
EDAP TMS SA, the global leader in robotic energy-based therapies, announced the publication of the full results from the HIFI study in European Urology, which has the highest impact factor amongst scientific journals focused in urology. The study evaluated high-intensity focused ultrasound versus radical prostatectomy as a first line treatment of localized prostate cancer.
Clinical Roundup
New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that one’s biological age, which can be higher than his or her chronological age – a concept called accelerated aging – may predict who’s at risk for developing colon polyps, a known risk factor for colorectal cancer.
Clinical Roundup
An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed.
Clinical Roundup
A new study, published in Nature Communications and led by the University of Minnesota Medical School and Duke University, found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. The new blood-based test — called AR-ctDETECT — is designed to detect and analyze small fragments of tumor-derived DNA in the blood of certain patients with advanced, metastatic prostate cancer.
Clinical Roundup
A study published in JAMA Network Open underscored the importance of utilizing genetic ancestry beyond self-reported race in prognosticating breast cancer outcomes for Black women and addressing their disproportionately higher mortality rate.
Drugs & Targets
FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Drugs & Targets
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
Drugs & Targets
PolyPid Ltd. announced a new research and development collaboration with ImmunoGenesis Inc. The collaboration focuses on the development of novel formulations utilizing PolyPid’s experience with its proprietary PLEX Technology and ImmunoGenesis’ potent STimulator of INterferon Genes agonist drug candidate to potentially enhance treatment for solid tumors.
Drugs & Targets
Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
NCI Director's Report
NCI is temporarily reducing its paylines as the federal government is being funded at FY2024 levels via a continuing resolution that extends until Dec. 20, delaying the budgeting process for most federal agencies in the new fiscal year.
NCI is establishing an Early-Onset Cancer Initiative to address the reported rise in early-onset cancer. The initiative will focus on the biological mechanisms of early-onset cancer, the interactions between several known risk factors, and prevention strategies.
News Analysis
Robert F. Kennedy Jr., an anti-vaccine activist whom Trump has chosen to run HHS, would have the capacity to roll back core public health protections, including protections for people with cancer, and dismantle research related to infectious diseases, public health experts warn.
Guest Editorial
Young adults with cancer are starting to break the silence about grief. Most people think of grief following the death of a loved one, but grief can accompany any event that disrupts or challenges our sense of normalcy or ourselves.1 During this first week of December, National Grief Awareness Week, we can raise awareness about grief in young adults with cancer to help ensure that no one grieves alone.
In the Archives
On Dec. 23, 1971, President Richard Nixon signed the National Cancer Act into law.
In Brief
Michael Wong joined Roswell Park Comprehensive Cancer Center as the center’s first physician-in-chief.
In Brief
Andrew M. EvensPhillip ScheinbergThe British Journal of Haematology announced the appointment of Andrew M. Evens as its editor-in-chief, effective Jan. 1, 2025.
In Brief
The President’s Cancer Panel released a report, Enhancing Patient Navigation with Technology to Improve Equity in Cancer Care, as part of a White House event acknowledging advancements in navigation support for cancer patients over the past year. The report calls on healthcare organizations, policymakers, and technology developers to keep pace with the rapid advancement and adoption of new technology.
In Brief
Break Through Cancer has launched the PoweRD 2 Cure ALK+ Lung Cancer TeamLab, a collaboration among nine leading cancer research institutions, including Break Through Cancer’s five partner institutions: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT’s Koch Institute for Integrative Cancer Research, and the University of Texas MD Anderson Cancer Center, as well as newly engaged collaborators from Mass General Brigham, Boston Children’s Hospital, the University of Colorado Cancer Center and Vanderbilt University Medical Center.
In Brief
Siemens Healthineers and The Ohio State Wexner Medical Center have expanded their existing strategic relationship to form a 10-year, $105 million value partnership to foster breakthroughs in clinical care, in addition to their longstanding research collaboration.
In Brief
To meet the growing demands for cancer treatment in Tarrant County and surrounding areas, UT Southwestern Medical Center is expanding its cancer services in the Fort Worth Medical District with construction of a two-story radiation oncology campus that will house the city’s first MRI-guided precision radiation treatment.
In Brief
Researchers at Baylor College of Medicine and Rice University received a $2.3 million Breakthrough Award from the Department of Defense Congressionally Directed Medical Research Programs to develop a novel NanoGel antibody therapy that targets ER+ breast cancer that has metastasized to bone.
In Brief
A team of UNC-Chapel Hill researchers has been awarded up to $10 million in Advanced Research Projects Agency for Health funding to develop the Cancer Identification and Precision Oncology Center (CIPOC).
In Brief
UVA Cancer Center, Appalachian Community Cancer Alliance, and Buchanan General Hospital have teamed up to make getting screened for lung cancer easier for residents of rural Virginia and West Virginia.
In Brief
Asia Society Policy Institute’s Center for China Analysis and Cure4Cancer jointly published “Advancing Global Health Equity: Expanding the U.S.-Australia Cancer Alliance Toward an Asia-Pacific Collaborative Effort to Save Millions of Lives.”
Clinical Roundup
Colorectal cancer screening is an effective tool for catching the disease early when it’s most treatable, yet it is underutilized in patient populations who receive primary care at federally qualified health centers.
Clinical Roundup
Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas.
Clinical Roundup
Genentech’s phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer, did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.
Clinical Roundup
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia who were treated with the novel anti-CD19 chimeric antigen receptor T-cell therapy, obecabtagene autoleucel, experienced high response rates and most did not need a subsequent stem cell transplant, according to results from the phase Ib/II FELIX trial co-led by researchers at the University of Texas MD Anderson Cancer Center.
Clinical Roundup
A study published in the journal Nature reports results of the first-in-human phase I clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3. Researchers at Baylor College of Medicine and Texas Children’s Cancer Center led the study, which tested chimeric antigen receptor T cells enhanced with the protein interleukin-15.
Clinical Roundup
David B. Weiner, of the Wistar Institute, and his laboratory, created a new therapeutic design for glioblastoma, the deadliest form of brain cancer.
Clinical Roundup
A team at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute completed its first gene therapy for a patient with hemophilia B, the first at an adult medical center in Ohio.
Clinical Roundup
RWE and phase I data support the role of Orserdu for ER+, HER2- advanced or metastatic breast cancer
The Menarini Group and Stemline Therapeutics will present new and expanded data on Orserdu at the upcoming 2024 San Antonio Breast Cancer Symposium, held from Dec. 10-13. The company will bring real-world progression-free survival results of Orserdu in adult patients with ER+/HER2-, advanced or metastatic breast cancer. Additionally, the company will present updated efficacy results of elacestrant plus abemaciclib, along with a pooled safety analysis from phase Ib/2 of both the ELECTRA and ELEVATE trials.
Clinical Roundup
A new nationwide survey of more than 750 radiation oncologists confirms that prior authorization harms people with cancer by causing treatment delays, abandoned treatments, hospitalizations and patient deaths.
Clinical Roundup
Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.
Clinical Roundup
A cancer therapy that prompts the body’s immune defenses against viruses and bacteria to attack tumors can make patients more vulnerable to heart attack and stroke. A possible explanation for this side effect is that the treatment interferes with immune regulation in the heart’s largest blood vessels, a new study suggests.
Clinical Roundup
Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, a treatment for multiple myeloma. Their study was published this month in the journal Blood Neoplasia.
Clinical Roundup
Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.
Clinical Roundup
Laboratory experiments with cancer cells reveal two ways in which tumors evade chemotherapy drugs designed to starve and kill them, a new study in Nature Metabolism shows.
Drugs & Targets
FDA has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for adults
Drugs & Targets
Merus a clinical-stage oncology company developing innovative, full-length multispecific antibodies and Partner Therapeutics Inc., a private, fully-integrated biotechnology company with a focus in hematology and oncology, announced they have entered into an agreement in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab (Zeno, also called Bizengri) for the treatment of NRG1 fusion-positive cancer in the U.S.
Drugs & Targets
ConcertAI announced a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization.
NCI Trials
The National Cancer Institute approved the following clinical research studies last month.
Capitol Hill
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
One year after the Centers for Medicare & Medicaid Services made the decision to pay for patient navigation services, data from early adopters show that navigation services are leading to better outcomes, significant cost savings for healthcare systems, and mitigation of health inequities.
Health Equity
The NCI Cancer Center Support Grant requires community outreach and engagement, but the design and implementation of COE programs, as well as staff training, are largely left to individual institutions.
By McKenzie Prillaman
Trials & Tribulations
The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia.
In the Archives
When Larry Einhorn was a young physician in the early 1970s, actinomycin-D was the standard drug used to treat testicular cancer. It was—and still is—the most common carcinoma in young men ages 15-35.
By McKenzie Prillaman
In Brief
Krish Patel was appointed director of lymphoma research at Sarah Cannon Research Institute.
In Brief
Robert Schnoll, Penn Medicine’s Abramson Cancer Center’s associate director for population science, was named the John H. Glick, MD Professor in Cancer Research. Schnoll is also the director of the Center for Interdisciplinary Research on Nicotine Addiction, a senior fellow in the Penn Center for Public Health, and co-director of the Community Research and Engagement Core at the Penn Center for AIDS Research.
In Brief
William K. Oh was appointed as service medical director of Smilow Cancer Hospital at Greenwich Hospital, as well as director of precision medicine for Yale Cancer Center and Smilow Cancer Hospital.
In Brief
Roy S. Herbst (middle) receives his award at the Innovation Gala of The Chemotherapy+ Foundation, with Robert Winn (left), director and Lipman Chair in Oncology at VCU Massey Comprehensive Cancer Center, and Katerina Politi (right), scientific director of YCC’s Center for Thoracic Cancers.Roy S. Herbst was awarded the Ezra Greenspan Award at the Innovation Gala of The Chemotherapy+ Foundation on Nov. 19 in New York City.
In Brief
Jupiter Bioventures, a biotechnology venture foundry that builds science-driven therapeutics companies, announced the closing of a $70 million initial financing.
In Brief
The U.S. Department of Energy’s Argonne National Laboratory will use its world-leading capabilities in artificial intelligence and high-performance computing to research novel ways to fight cancer and advance vaccine discovery.
In Brief
The University of Cincinnati Cancer Center was granted $2.3 million from NCI to develop a technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.
In Brief
Marking a new era of non-invasive medical interventions, the Northwell Health Cancer Institute is investing $1.2 million in the development of cutting-edge histotripsy technology to treat some liver cancer tumors without surgery. This innovative approach uses targeted ultrasound beams to create microbubbles within tumors, effectively disrupting and destroying diseased cells without the need for incisions.
In Brief
The governing body of the Cancer Prevention and Research Institute of Texas approved $89 million through 22 grants to advance the state’s fight against cancer.
In Brief
The Lilabean Foundation for Pediatric Brain Cancer Research raised $900,000 at its 13th Annual Lilabean Foundation Fall Ball, held on Saturday, November 2. Proceeds from the Fall Ball will directly fund groundbreaking research initiatives focused on discovering new treatments and improving survival rates for children fighting pediatric brain cancer.
In Brief
TD Bank has committed $100,000 to support the MUSC Hollings Cancer Center’s SC AMEN program, a community outreach initiative that brings education, screenings, and health services assistance to Black men 40 to 69 years old in South Carolina.
Clinical Roundup
The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.
Clinical Roundup
Lung cancer is the leading cause of the cancer deaths in the U.S., but the American Lung Association’s 2024 “State of Lung Cancer” report reveals positive news.
Clinical Roundup
Merck announced positive topline results from the pivotal phase III MK-3475A-D77 trial.
Clinical Roundup
Exact Sciences Corp. presented three abstracts highlighting advancements in the development of a multi-cancer early detection test at the American Association for Cancer Research Special Conference in Cancer Research: Liquid Biopsy from Nov. 13-16, in San Diego, CA.
Clinical Roundup
Researchers at City of Hope found that taking white button mushroom pills reduces a class of immune cells called myeloid-derived suppressor cells, which has been linked to cancer development and spread.
Clinical Roundup
In a phase II clinical trial, a research team led by Nilofer Azad, professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat—a histone deacetylase inhibitor.
Clinical Roundup
Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.
